info@targetmol.com    Tel: (857) 239-0968 / (617) 419-7131
Home > c-Met
c-Met
Cat.No. Product Name Information Area
T3455 LY2801653 LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(... Cancer
T6907 NPS-1034 NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. Others
T6517 Golvatinib (E7050) Golvatinib (E7050) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM... Cancer
T6378 AMG-458 AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Me... Cancer
T6260 AMG-208 AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1. Cancer
T6154 SU11274 SU11274 is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR o... Cancer
T6128 PHA-665752 PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 ... Cancer
T6121 Tepotinib (EMD 1214063) Tepotinib (EMD 1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, ... Cancer
T6117 Tivantinib (ARQ 197) Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.35... Cancer
T6095 JNJ-38877605 JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold sel... Cancer
T6094 MK-2461 MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-... Cancer
T3113 Foretinib Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for ... Cancer
T2699 BMS-777607 BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 ... Endocrine system
T2680 NVP-BVU972 NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. Cancer
T2676 PF-04217903 PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A54... Cancer
T2456 Tivozanib Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor r... Cancer
T2419 BMS794833 BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15... Cancer
T2349 BMS-754807 BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.... Cancer
T2293 SGX-523 SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-R... Cancer
T2282 RPI-1 RPI-1 reduced the phosphorylation of RET, MET, DCDB2, CTND1, and PLCγ。 Cancer
T2054 Altiratinib Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumo... Cancer
T1963 INCB28060(Capmatinib) Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.... Other
T1661 Crizotinibhot Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small ce... Cancer
T6351 MGCD-265 MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/... Cancer
1